MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Last updated: May 30, 2024
Sponsor: Pharmasoft
Overall Status: Completed

Phase

4

Condition

Glaucoma

Treatment

Mexidol

Clinical Study ID

NCT06437639
MexidolPOAG2024
  • Ages 50-65
  • All Genders

Study Summary

Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • An advanced stage of POAG in one or two eyes

  • Hypotonic-compensated intraocular pressure (IOP)

Exclusion

Exclusion Criteria:

  • Degenerative diseases of the central nervous system, diabetes mellitus

  • Primary mitochondrial dysfunction

  • A history of surgical interventions and damage to the organ of vision

  • Acute or chronic inflammatory or hereditary degenerative eye diseases (anterior andposterior sections)

  • Decompensation of concomitant somatic diseases

  • Taking antioxidants/nootropic drugs 6 months before inclusion in the study

  • Hypersensitivity to ethylmethylhydroxypyridine succinate or to any of the excipients

Study Design

Total Participants: 80
Treatment Group(s): 1
Primary Treatment: Mexidol
Phase: 4
Study Start date:
September 15, 2023
Estimated Completion Date:
February 02, 2024

Study Description

Hypothesis: Mexidol® allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function

Connect with a study center

  • Tyumen Scientific Center of the Russian Academy of Sciences

    Tyumen, 625026
    Russian Federation

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.